TABLE 41–5 Summary of bioavailability characteristics of the insulins. Insulin Preparations Onset of Action Peak Action Effective Duration Insulins lispro, aspart, glulisine 5–15 min 1–1.5 h 3–4 h Human regular 30–60 min 2 h 6–8 h Technosphere inhaled insulin 5–15 min 1 h 3 h Human NPH 2–4 h 6–7 h 10–20 h Insulin glargine 0.5–1 h Flat ∼24 h Insulin detemir 0.5–1 h Flat 17 h Insulin degludec 0.5–1.5 h Flat >42 h TABLE 41–6 Some insulin preparations available in the United States. Preparation Species Source Concentration Short­acting insulins Insulin lispro (Humalog, Lyumjev, Lilly; Admelog, sanofi­aventis) Human analog U100 U200 (Humalog and Lyumjev only) Insulin aspart, insulin aspart niacinamide (Novolog, Fiasp, Novo Nordisk) Human analog U100 Insulin glulisine (Apidra, sanofi­aventis) Human analog U100 Regular insulin (Humulin R, Lilly; Novolin R, Novo Nordisk) Human U100 U500 (Humulin R only) Regular insulin inhaled (MannKind) Human — Long­acting insulins NPH insulin (Humulin N, Lilly; Novolin N, Novo Nordisk) Human U100 Insulin glargine (Lantus, Toujeo, sanofi­aventis; Basaglar, Rezvoglar, Lilly; Semglee,1 Mylan) Human analog U100 U300 (Toujeo only) Insulin detemir (Levemir, Novo Nordisk) Human analog U100 Insulin degludec (Tresiba, Novo Nordisk) Human analog U100, U200 Premixed insulins